Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques

Joseph F. Poduslo, Geoffry L. Curran, Jane A. Peterson, Daniel J Mc Cormick, Abdul H. Fauq, Murad A. Khan, Thomas M. Wengenack

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Molecular imaging is an important new direction in medical diagnosis; however, its success is dependent upon molecular probes that demonstrate selective tissue targeting. We report the design and chemical synthesis of a derivative of human amyloid-β (Aβ) peptide that is capable of selectively targeting individual amyloid plaques in the brain of Alzheimer's disease transgenic mice after being intravenously injected. This derivative is based on the sequence of the first 30 amino acid residues of Aβ with asparagyl/glutamyl-4-aminobutane residues (N-4ab/Q-4ab) substituted at unique Asp and Glu positions and with Gd-DTPA-aminohexanoic acid covalently attached at the N-terminal Asp. The Gd[N-4ab/Q-4ab]Aβ30 peptide was homogeneous as shown by high-resolution analytical techniques with a mass of ±4385 Da determined by electrospray ionization mass spectrometry. This diamine- and gadolinium-substituted derivative of Aβ is shown to have enhanced in vitro binding to Alzheimer's disease (AD) amyloid plaques and increased in vivo permeability at the blood-brain barrier because of the unique Asp/Glu substitutions. In addition, specific in vivo targeting to AD amyloid plaques is demonstrated throughout the brain of an APP, PS1 transgenic mouse after intravenous injection. Because of the magnetic resonance (MR) imaging contrast enhancement provided by gadolinium, this derivative should enable the in vivo MR imaging of individual amyloid plaques in the brains of AD animals or patients to allow for early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

Original languageEnglish (US)
Pages (from-to)6064-6075
Number of pages12
JournalBiochemistry
Volume43
Issue number20
DOIs
StatePublished - May 25 2004

Fingerprint

Amyloid Plaques
Magnetic resonance
Blood-Brain Barrier
Amyloid
Contrast Media
Permeability
Alzheimer Disease
Magnetic Resonance Spectroscopy
Gadolinium
Brain Diseases
Transgenic Mice
Derivatives
Aminocaproates
Brain
Magnetic Resonance Imaging
Molecular Probes
Gadolinium DTPA
Peptides
Molecular Imaging
Diamines

ASJC Scopus subject areas

  • Biochemistry

Cite this

Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. / Poduslo, Joseph F.; Curran, Geoffry L.; Peterson, Jane A.; Mc Cormick, Daniel J; Fauq, Abdul H.; Khan, Murad A.; Wengenack, Thomas M.

In: Biochemistry, Vol. 43, No. 20, 25.05.2004, p. 6064-6075.

Research output: Contribution to journalArticle

Poduslo, Joseph F. ; Curran, Geoffry L. ; Peterson, Jane A. ; Mc Cormick, Daniel J ; Fauq, Abdul H. ; Khan, Murad A. ; Wengenack, Thomas M. / Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. In: Biochemistry. 2004 ; Vol. 43, No. 20. pp. 6064-6075.
@article{07f09a3c31a84fa989cb97c7cbe15a7e,
title = "Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques",
abstract = "Molecular imaging is an important new direction in medical diagnosis; however, its success is dependent upon molecular probes that demonstrate selective tissue targeting. We report the design and chemical synthesis of a derivative of human amyloid-β (Aβ) peptide that is capable of selectively targeting individual amyloid plaques in the brain of Alzheimer's disease transgenic mice after being intravenously injected. This derivative is based on the sequence of the first 30 amino acid residues of Aβ with asparagyl/glutamyl-4-aminobutane residues (N-4ab/Q-4ab) substituted at unique Asp and Glu positions and with Gd-DTPA-aminohexanoic acid covalently attached at the N-terminal Asp. The Gd[N-4ab/Q-4ab]Aβ30 peptide was homogeneous as shown by high-resolution analytical techniques with a mass of ±4385 Da determined by electrospray ionization mass spectrometry. This diamine- and gadolinium-substituted derivative of Aβ is shown to have enhanced in vitro binding to Alzheimer's disease (AD) amyloid plaques and increased in vivo permeability at the blood-brain barrier because of the unique Asp/Glu substitutions. In addition, specific in vivo targeting to AD amyloid plaques is demonstrated throughout the brain of an APP, PS1 transgenic mouse after intravenous injection. Because of the magnetic resonance (MR) imaging contrast enhancement provided by gadolinium, this derivative should enable the in vivo MR imaging of individual amyloid plaques in the brains of AD animals or patients to allow for early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.",
author = "Poduslo, {Joseph F.} and Curran, {Geoffry L.} and Peterson, {Jane A.} and {Mc Cormick}, {Daniel J} and Fauq, {Abdul H.} and Khan, {Murad A.} and Wengenack, {Thomas M.}",
year = "2004",
month = "5",
day = "25",
doi = "10.1021/bi0359574",
language = "English (US)",
volume = "43",
pages = "6064--6075",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "20",

}

TY - JOUR

T1 - Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques

AU - Poduslo, Joseph F.

AU - Curran, Geoffry L.

AU - Peterson, Jane A.

AU - Mc Cormick, Daniel J

AU - Fauq, Abdul H.

AU - Khan, Murad A.

AU - Wengenack, Thomas M.

PY - 2004/5/25

Y1 - 2004/5/25

N2 - Molecular imaging is an important new direction in medical diagnosis; however, its success is dependent upon molecular probes that demonstrate selective tissue targeting. We report the design and chemical synthesis of a derivative of human amyloid-β (Aβ) peptide that is capable of selectively targeting individual amyloid plaques in the brain of Alzheimer's disease transgenic mice after being intravenously injected. This derivative is based on the sequence of the first 30 amino acid residues of Aβ with asparagyl/glutamyl-4-aminobutane residues (N-4ab/Q-4ab) substituted at unique Asp and Glu positions and with Gd-DTPA-aminohexanoic acid covalently attached at the N-terminal Asp. The Gd[N-4ab/Q-4ab]Aβ30 peptide was homogeneous as shown by high-resolution analytical techniques with a mass of ±4385 Da determined by electrospray ionization mass spectrometry. This diamine- and gadolinium-substituted derivative of Aβ is shown to have enhanced in vitro binding to Alzheimer's disease (AD) amyloid plaques and increased in vivo permeability at the blood-brain barrier because of the unique Asp/Glu substitutions. In addition, specific in vivo targeting to AD amyloid plaques is demonstrated throughout the brain of an APP, PS1 transgenic mouse after intravenous injection. Because of the magnetic resonance (MR) imaging contrast enhancement provided by gadolinium, this derivative should enable the in vivo MR imaging of individual amyloid plaques in the brains of AD animals or patients to allow for early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

AB - Molecular imaging is an important new direction in medical diagnosis; however, its success is dependent upon molecular probes that demonstrate selective tissue targeting. We report the design and chemical synthesis of a derivative of human amyloid-β (Aβ) peptide that is capable of selectively targeting individual amyloid plaques in the brain of Alzheimer's disease transgenic mice after being intravenously injected. This derivative is based on the sequence of the first 30 amino acid residues of Aβ with asparagyl/glutamyl-4-aminobutane residues (N-4ab/Q-4ab) substituted at unique Asp and Glu positions and with Gd-DTPA-aminohexanoic acid covalently attached at the N-terminal Asp. The Gd[N-4ab/Q-4ab]Aβ30 peptide was homogeneous as shown by high-resolution analytical techniques with a mass of ±4385 Da determined by electrospray ionization mass spectrometry. This diamine- and gadolinium-substituted derivative of Aβ is shown to have enhanced in vitro binding to Alzheimer's disease (AD) amyloid plaques and increased in vivo permeability at the blood-brain barrier because of the unique Asp/Glu substitutions. In addition, specific in vivo targeting to AD amyloid plaques is demonstrated throughout the brain of an APP, PS1 transgenic mouse after intravenous injection. Because of the magnetic resonance (MR) imaging contrast enhancement provided by gadolinium, this derivative should enable the in vivo MR imaging of individual amyloid plaques in the brains of AD animals or patients to allow for early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

UR - http://www.scopus.com/inward/record.url?scp=2442641602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442641602&partnerID=8YFLogxK

U2 - 10.1021/bi0359574

DO - 10.1021/bi0359574

M3 - Article

C2 - 15147190

AN - SCOPUS:2442641602

VL - 43

SP - 6064

EP - 6075

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 20

ER -